536 related articles for article (PubMed ID: 24284392)
1. Lessons from mouse models of high-fat diet-induced NAFLD.
Nakamura A; Terauchi Y
Int J Mol Sci; 2013 Oct; 14(11):21240-57. PubMed ID: 24284392
[TBL] [Abstract][Full Text] [Related]
2. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice.
Tajima K; Nakamura A; Shirakawa J; Togashi Y; Orime K; Sato K; Inoue H; Kaji M; Sakamoto E; Ito Y; Aoki K; Nagashima Y; Atsumi T; Terauchi Y
Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E987-98. PubMed ID: 23964070
[TBL] [Abstract][Full Text] [Related]
3. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Soejima Y; Fukusato T
World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421
[TBL] [Abstract][Full Text] [Related]
4. Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance.
Nakamura A; Tajima K; Zolzaya K; Sato K; Inoue R; Yoneda M; Fujita K; Nozaki Y; Kubota KC; Haga H; Kubota N; Nagashima Y; Nakajima A; Maeda S; Kadowaki T; Terauchi Y
Diabetologia; 2012 Dec; 55(12):3382-91. PubMed ID: 22955994
[TBL] [Abstract][Full Text] [Related]
5. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
6. An Obesogenic Dietary Mouse Model of Nonalcoholic Steatohepatitis.
Zarrouki B; Boucher J
Methods Mol Biol; 2020; 2164():121-127. PubMed ID: 32607889
[TBL] [Abstract][Full Text] [Related]
7. GADD34-deficient mice develop obesity, nonalcoholic fatty liver disease, hepatic carcinoma and insulin resistance.
Nishio N; Isobe K
Sci Rep; 2015 Aug; 5():13519. PubMed ID: 26316333
[TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
[TBL] [Abstract][Full Text] [Related]
10. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
Hymel E; Vlock E; Fisher KW; Farazi PA
PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
[TBL] [Abstract][Full Text] [Related]
11. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.
Dowman JK; Hopkins LJ; Reynolds GM; Nikolaou N; Armstrong MJ; Shaw JC; Houlihan DD; Lalor PF; Tomlinson JW; Hübscher SG; Newsome PN
Am J Pathol; 2014 May; 184(5):1550-61. PubMed ID: 24650559
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
13. Fructose as a key player in the development of fatty liver disease.
Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
[TBL] [Abstract][Full Text] [Related]
14. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
16. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
Starley BQ; Calcagno CJ; Harrison SA
Hepatology; 2010 May; 51(5):1820-32. PubMed ID: 20432259
[TBL] [Abstract][Full Text] [Related]
18. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non-alcoholic steatohepatitis models.
Gwag T; Ma E; Zhou C; Wang S
Liver Int; 2022 Apr; 42(4):829-841. PubMed ID: 35129307
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
